Bottom line
Is RFIMX a good fund? The bottom line
RFIMX is the Institutional Class share class of Ranger Micro Cap Fund, an actively managed small-cap mutual fund from Spend Life Wisely.
Annual fees run 1.28% — about $128 a year on every $10,000 invested, more expensive than 76% of small-cap funds we track.
It returned +11.9% over one year, +12.1% a year over five years (as of Dec 31, 2024, per its prospectus).
With $11.7 million in net assets and 49 holdings, its largest position is Ligand Pharmaceuticals, Inc. (5.6%) and the top 10 make up 35.3% of the portfolio.
What stands out
- 5-year return beat 95% of category peers
What to watch
- Expensive for its category (1.28%)
- Small fund ($11.7 million) — small funds are likelier to close
Updated Nov 19, 2026
What RFIMX invests in
The Fund seeks long-term capital appreciation.
"Principal Investment Strategies: Under normal market conditions, the Fund invests at least 80% of its assets in common stocks of micro capitalization (""micro cap"") companies. The Micro Cap Growth Strategy seeks long-term growth of capital by investing primarily in common stocks of growth-oriented domestic issuers which, at the initial time of purchase are within the capitalization range of issuers represented within the Russell Microcap Growth Index. As of the most recent reconstitution date of April 30, 2025, the market capitalization range was $30.3 million to $1.3 billion. RIM's strategy begins by narrowing the microcap stock universe to identify companies that RIM believes have a proven track record of competitive advantages and the ability to produce sustainable value for shareholders in the foreseeable future. From this group, RIM selects securities that it believes are…
From the fund's prospectus (filed Dec 1, 2025).
RFIMX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RFIMX | +11.9% | +12.1% | — |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2024
What RFIMX costs
On a $10,000 investment, RFIMX's 1.28% expense ratio costs about $128 a year. The prospectus estimates $2,260 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
RFIMX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Ligand Pharmaceuticals, Inc. | 5.60% |
| 2 | PDF Solutions, Inc. | 4.05% |
| 3 | Karat Packaging, Inc. | 4.01% |
| 4 | The Pennant Group, Inc. | 3.49% |
| 5 | Fidelity Institutional Cash Portfolios | 3.20% |
| 6 | Business First Bancshares, Inc. | 3.10% |
| 7 | Phibro Animal Health Corp | 3.07% |
| 8 | iRadimed Corp. | 3.06% |
| 9 | Metropolitan Bank Holding Corp. | 2.94% |
| 10 | UFP Technologies, Inc. | 2.79% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 35.3% of the fund. See all top 25 holdings and asset mix →